And thats the short list
AAV vectors are generally safe at therapeutic doses eight AAV-based gene therapies have been FDA-approved as of 2024 but at high doses, above roughly 10^14 viral genomes per kilogram, the literature documents immune reactions, liver toxicity, and in rare cases, genotoxicity
Korkmaz OT, Ay H, Aytan N et al (2019) Vasoactive intestinal peptide decreases -amyloid accumulation and prevents brain atrophy in the 5xFAD mouse model of Alzheimers disease
The main differences across comparison categories are: Receptor Targets: advantage goes to Retatrutide
Provides stability its lab-made structure offers consistent performance in laboratory testing
At a physical level, these include anemia, exhaustion, loss of appetite, nerve pain, muscle tremor, coordination disorders, and tingling or a sense of numbness in the legs